The global psoriasis drugs market is expected to be valued at $21.4 billion by 2022, as per a new report. The increasing number of reimbursement policies for treatment, advanced diagnostic tools, raised disease awareness and improved technological systems are likely to increase the adoption of therapeutics.
Additionally, the rising prevalence and incidence of psoriasis is anticipated to fuel the market growth. The condition has neither exact causes nor treatments to cure. Certain environmental and genetic factors may trigger the disease onset. Most treatments for the condition target to decelerate the severity of the disease by stopping the keratinocyte hyperproliferation. The disease symptoms can be managed by following a healthy lifestyle.
Further key findings from the report suggest:
Tumor Necrosis Factor-inhibitors dominated the psoriasis therapeutic market in 2016 owing to its higher usage by healthcare practitioners and easy availability.
TNF-inhibitors are likely to lose market shares over the forecast period due to increasing adoption of IL-inhibitor therapy over conventional TNF-inhibitors
Interleukin-inhibitors sector is expected to grow at lucrative CAGR of 19.4% over the forecast period because of improved safety and efficacy profiles of Interleukin-inhibiting drugs.
The U.S. market is the dominant region in the psoriasis therapeutic space. It led the market in terms of revenue with $4.4 billion in 2016 due to the increasing number of patients seeking treatment and presence of well-established healthcare services.
In addition, presence of several key manufacturers in the U.S. and launch of novel drugs are some of the factors anticipated to increase the demand for therapeutics in this region
Japan is expected to be the fastest growing region over the next decade with lucrative CAGR of 13.0% from 2016 to 2022 due to growing awareness about the disease among the people. Furthermore, presence of a large target population and high unmet clinical needs are some of the factors expected to propel the growth of this region.
Some of the key players in this industry are AbbVie Inc., Amgen Inc., Johnson & Johnson, Novartis AG, Eli Lilly & Company, AstraZeneca and Celgene Corporation.
Most of the key players are focusing on strategies such as expansion of their product portfolios and collaborations, mergers, & acquisitions. The emergence of biosimilars is a rising trend adopted by these companies.
Boehringer Ingelheim, the largest animal health company in Georgia and its NexGard® PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) product, and the Atlanta Braves Foundation, the non-profit arm of the Atlanta Braves, are proud to...
One of the main roles of the spleen is to help the body's immune system fight infections. The spleen does this through producing and regulating antibodies ? antibody production is negatively affected in various conditions, including sepsis and...
Prominently featured in The Inner Circle, Lee C. Ferguson, DO, FACS is acknowledged as a Pinnacle Lifetime Member for his contributions as a Vascular Surgeon.
Dr. Ferguson, a distinguished dual board-certified vascular surgeon and endovascular...
The Honourable David J. McGuinty, Member of Parliament for Ottawa South, on behalf of the Honourable Mark Holland, Minister of Health, will hold a news conference to announce funding to improve palliative care.
MP McGuinty will be available to...
Sugar Kayne Radio, an innovative internet radio station founded by Matthew Kayne, also known as DJ Sugar Kayne, is set to launch on 2nd June. Located in the heart of North West London, Sugar Kayne Radio aims to revolutionize the online music...
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:
Today, the FDA published the FDA Voices: "A Milestone in Facilitating the Development of Safe and Effective Biosimilars," by Sarah Yim,...